TRUE FALSE 0000818479 12/31 2021 Q1 FALSE 0000818479 2021-01-01 2021-03-31 xbrli:shares 0000818479 2021-05-03 iso4217:USD 0000818479 2020-01-01 2020-03-31 iso4217:USD xbrli:shares 0000818479 2021-03-31 0000818479 2020-12-31 0000818479 us-gaap:CommonStockMember 2020-12-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000818479 us-gaap:RetainedEarningsMember 2020-12-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000818479 us-gaap:TreasuryStockMember 2020-12-31 0000818479 us-gaap:ParentMember 2020-12-31 0000818479 us-gaap:NoncontrollingInterestMember 2020-12-31 0000818479 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000818479 us-gaap:ParentMember 2021-01-01 2021-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000818479 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000818479 us-gaap:CommonStockMember 2021-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000818479 us-gaap:RetainedEarningsMember 2021-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000818479 us-gaap:TreasuryStockMember 2021-03-31 0000818479 us-gaap:ParentMember 2021-03-31 0000818479 us-gaap:NoncontrollingInterestMember 2021-03-31 0000818479 us-gaap:CommonStockMember 2019-12-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000818479 us-gaap:RetainedEarningsMember 2019-12-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000818479 us-gaap:TreasuryStockMember 2019-12-31 0000818479 us-gaap:ParentMember 2019-12-31 0000818479 us-gaap:NoncontrollingInterestMember 2019-12-31 0000818479 2019-12-31 0000818479 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000818479 us-gaap:ParentMember 2020-01-01 2020-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000818479 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000818479 us-gaap:CommonStockMember 2020-03-31 0000818479 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000818479 us-gaap:RetainedEarningsMember 2020-03-31 0000818479 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000818479 us-gaap:TreasuryStockMember 2020-03-31 0000818479 us-gaap:ParentMember 2020-03-31 0000818479 us-gaap:NoncontrollingInterestMember 2020-03-31 0000818479 2020-03-31 0000818479 us-gaap:TradeAccountsReceivableMember 2021-03-31 0000818479 us-gaap:TradeAccountsReceivableMember 2020-12-31 0000818479 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000818479 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000818479 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0000818479 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2020-12-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2021-01-01 2021-03-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2021-03-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2019-12-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2020-01-01 2020-03-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000818479 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000818479 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000818479 xray:AccumulatedNetGainLossFromDerivativesNotDesignatedAsCashFlowHedgesAttributableToParentMember 2020-03-31 0000818479 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000818479 xray:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestTranslationGainLossMember 2021-03-31 0000818479 xray:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestTranslationGainLossMember 2020-12-31 0000818479 xray:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestNetInvestmentHedgesMember 2021-03-31 0000818479 xray:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestNetInvestmentHedgesMember 2020-12-31 0000818479 xray:StockOptionsAndRestrictedStockUnitsMember 2021-01-01 2021-03-31 0000818479 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000818479 xray:DatumDentalLtdMember 2021-01-21 2021-01-21 0000818479 xray:DatumDentalLtdMember 2021-01-21 xbrli:pure 0000818479 xray:DatumDentalLtdMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-21 2021-01-21 0000818479 xray:DatumDentalLtdMember srt:MinimumMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-21 2021-01-21 0000818479 srt:MaximumMember xray:DatumDentalLtdMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-21 2021-01-21 0000818479 us-gaap:InProcessResearchAndDevelopmentMember xray:DatumDentalLtdMember 2021-01-21 2021-01-21 0000818479 xray:StraightSmileLLCMember 2020-12-31 0000818479 xray:StraightSmileLLCMember 2020-12-31 2020-12-31 0000818479 xray:StraightSmileLLCMember 2021-01-01 2021-03-31 0000818479 us-gaap:NoncompeteAgreementsMember xray:StraightSmileLLCMember 2020-12-31 2020-12-31 0000818479 xray:StraightSmileLLCMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-12-31 2020-12-31 0000818479 us-gaap:TrademarksAndTradeNamesMember xray:StraightSmileLLCMember 2020-12-31 2020-12-31 0000818479 xray:InvestmentCastingBusinessMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-02-01 2021-02-01 0000818479 xray:InvestmentCastingBusinessMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-03-31 xray:segment 0000818479 xray:TechnologiesAndEquipmentSegmentMember 2021-01-01 2021-03-31 0000818479 xray:TechnologiesAndEquipmentSegmentMember 2020-01-01 2020-03-31 0000818479 xray:ConsumablesSegmentMember 2021-01-01 2021-03-31 0000818479 xray:ConsumablesSegmentMember 2020-01-01 2020-03-31 0000818479 us-gaap:OperatingSegmentsMember xray:TechnologiesAndEquipmentSegmentMember 2021-01-01 2021-03-31 0000818479 us-gaap:OperatingSegmentsMember xray:TechnologiesAndEquipmentSegmentMember 2020-01-01 2020-03-31 0000818479 us-gaap:OperatingSegmentsMember xray:ConsumablesSegmentMember 2021-01-01 2021-03-31 0000818479 us-gaap:OperatingSegmentsMember xray:ConsumablesSegmentMember 2020-01-01 2020-03-31 0000818479 us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000818479 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000818479 xray:CorporateReconcilingItemsAndEliminationsMember 2021-01-01 2021-03-31 0000818479 xray:CorporateReconcilingItemsAndEliminationsMember 2020-01-01 2020-03-31 0000818479 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-03-31 0000818479 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000818479 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0000818479 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000818479 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0000818479 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000818479 xray:RestructuringAndOtherCostsMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringAndOtherCostsMember 2020-01-01 2020-03-31 0000818479 us-gaap:FacilityClosingMember srt:MinimumMember xray:August2020PlanMember 2020-08-06 2020-08-06 0000818479 us-gaap:FacilityClosingMember srt:MaximumMember xray:August2020PlanMember 2020-08-06 2020-08-06 0000818479 srt:MinimumMember xray:August2020PlanMember 2020-08-06 0000818479 srt:MaximumMember xray:August2020PlanMember 2020-08-06 0000818479 xray:August2020PlanMember 2021-01-01 2021-03-31 0000818479 xray:InventoryWriteDownMember xray:August2020PlanMember 2021-01-01 2021-03-31 0000818479 xray:FixedAssetDepreciationMember xray:August2020PlanMember 2021-01-01 2021-03-31 0000818479 us-gaap:EmployeeSeveranceMember xray:August2020PlanMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2019AndPriorPlansMember us-gaap:EmployeeSeveranceMember 2020-12-31 0000818479 xray:RestructuringFiscal2020PlansMember us-gaap:EmployeeSeveranceMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:EmployeeSeveranceMember 2020-12-31 0000818479 us-gaap:EmployeeSeveranceMember 2020-12-31 0000818479 xray:RestructuringFiscal2019AndPriorPlansMember us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2020PlansMember us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0000818479 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2019AndPriorPlansMember us-gaap:EmployeeSeveranceMember 2021-03-31 0000818479 xray:RestructuringFiscal2020PlansMember us-gaap:EmployeeSeveranceMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:EmployeeSeveranceMember 2021-03-31 0000818479 us-gaap:EmployeeSeveranceMember 2021-03-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2019AndPriorPlansMember 2020-12-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2020PlansMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OtherRestructuringMember 2020-12-31 0000818479 us-gaap:OtherRestructuringMember 2020-12-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2019AndPriorPlansMember 2021-01-01 2021-03-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2020PlansMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OtherRestructuringMember 2021-01-01 2021-03-31 0000818479 us-gaap:OtherRestructuringMember 2021-01-01 2021-03-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2019AndPriorPlansMember 2021-03-31 0000818479 us-gaap:OtherRestructuringMember xray:RestructuringFiscal2020PlansMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OtherRestructuringMember 2021-03-31 0000818479 us-gaap:OtherRestructuringMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:TechnologiesAndEquipmentSegmentMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:TechnologiesAndEquipmentSegmentMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:TechnologiesAndEquipmentSegmentMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:ConsumablesSegmentMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:ConsumablesSegmentMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:OperatingSegmentsMember xray:ConsumablesSegmentMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:CorporateNonSegmentMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember us-gaap:CorporateNonSegmentMember 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember 2020-12-31 0000818479 xray:RestructuringFiscal2021PlansMember 2021-01-01 2021-03-31 0000818479 xray:RestructuringFiscal2021PlansMember 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2021-03-31 0000818479 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2021-03-31 0000818479 us-gaap:NondesignatedMember 2021-03-31 0000818479 us-gaap:ForeignExchangeForwardMember 2021-01-01 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-03-31 iso4217:SEK 0000818479 us-gaap:ForeignExchangeForwardMember 2021-01-06 0000818479 us-gaap:CostOfSalesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueHedgingMember us-gaap:OtherExpenseMember 2021-01-01 2021-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2021-01-01 2021-03-31 0000818479 us-gaap:CostOfSalesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:OtherExpenseMember 2020-01-01 2020-03-31 0000818479 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-03-31 0000818479 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 0000818479 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2021-03-31 0000818479 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2021-03-31 0000818479 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:OtherNoncurrentAssetsMember 2021-03-31 0000818479 us-gaap:AccruedLiabilitiesMember xray:CrossCurrencyBasisSwapsMember 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:OtherNoncurrentLiabilitiesMember 2021-03-31 0000818479 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 0000818479 us-gaap:OtherNoncurrentAssetsMember 2021-03-31 0000818479 us-gaap:AccruedLiabilitiesMember 2021-03-31 0000818479 us-gaap:OtherNoncurrentLiabilitiesMember 2021-03-31 0000818479 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0000818479 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2020-12-31 0000818479 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2020-12-31 0000818479 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2020-12-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:OtherNoncurrentAssetsMember 2020-12-31 0000818479 us-gaap:AccruedLiabilitiesMember xray:CrossCurrencyBasisSwapsMember 2020-12-31 0000818479 xray:CrossCurrencyBasisSwapsMember us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0000818479 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0000818479 us-gaap:OtherNoncurrentAssetsMember 2020-12-31 0000818479 us-gaap:AccruedLiabilitiesMember 2020-12-31 0000818479 us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0000818479 us-gaap:ForeignExchangeContractMember 2021-03-31 0000818479 xray:CrossCurrencyBasisSwapsMember 2021-03-31 0000818479 us-gaap:ForeignExchangeContractMember 2020-12-31 0000818479 us-gaap:InterestRateSwapMember 2020-12-31 0000818479 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000818479 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000818479 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0000818479 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member xray:CrossCurrencyBasisSwapsMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member xray:ContingentConsiderationsOnAcquisitionsMember 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member xray:CrossCurrencyBasisSwapsMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:CrossCurrencyBasisSwapsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member xray:ContingentConsiderationsOnAcquisitionsMember 2020-12-31 0000818479 us-gaap:FairValueMeasurementsRecurringMember xray:ContingentConsiderationsOnAcquisitionsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000818479 us-gaap:LineOfCreditMember us-gaap:CommercialPaperMember 2021-03-31 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2021-03-31 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2020-12-31 0000818479 us-gaap:LineOfCreditMember us-gaap:CommercialPaperMember 2020-12-31 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2020-04-09 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2020-04-09 2020-04-09 0000818479 us-gaap:LineOfCreditMember xray:A2018RevolvingCreditFacilityMember 2020-04-17 0000818479 us-gaap:LineOfCreditMember xray:A2018RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-17 2020-04-17 0000818479 us-gaap:LineOfCreditMember xray:A2018RevolvingCreditFacilityMember 2020-05-26 2020-05-26 0000818479 xray:SeniorUnsecuredNotesMaturingJune12030Member us-gaap:SeniorNotesMember 2020-05-26 0000818479 xray:SeniorUnsecuredNotesMaturingJune12030Member us-gaap:SeniorNotesMember 2020-05-26 2020-05-26 0000818479 xray:SeniorUnsecuredNotesMaturingJune12030Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2020-05-26 2020-05-26 0000818479 xray:SeniorUnsecuredNotesMaturingJune12030Member us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2020-05-26 0000818479 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2020-05-26 2020-05-26 iso4217:EUR 0000818479 us-gaap:LineOfCreditMember xray:RevolvingCreditFacilityMaturingApril302021Member 2020-06-30 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2020-04-01 2020-06-30 0000818479 us-gaap:LineOfCreditMember xray:RevolvingCreditFacilityMaturingMay62021Member 2020-06-30 iso4217:JPY 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2020-06-30 0000818479 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2021-03-31 0000818479 xray:MISImplantsTechnologiesLtd.AndHealthcareConsumableBusinessMember xray:TechnologiesAndEquipmentSegmentMember 2021-03-31 0000818479 xray:TechnologiesAndEquipmentSegmentMember xray:EquipmentAndInstrumentsReportingUnitMember 2021-03-31 0000818479 us-gaap:TrademarksAndTradeNamesMember xray:EquipmentAndInstrumentsReportingUnitMember 2021-03-31 0000818479 xray:TechnologiesAndEquipmentSegmentMember 2020-12-31 0000818479 xray:ConsumablesSegmentMember 2020-12-31 0000818479 xray:TechnologiesAndEquipmentSegmentMember 2021-03-31 0000818479 xray:ConsumablesSegmentMember 2021-03-31 0000818479 xray:PatentsAndDevelopedTechnologyMember 2021-03-31 0000818479 xray:PatentsAndDevelopedTechnologyMember 2020-12-31 0000818479 us-gaap:TrademarksAndTradeNamesMember 2021-03-31 0000818479 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0000818479 us-gaap:LicensingAgreementsMember 2021-03-31 0000818479 us-gaap:LicensingAgreementsMember 2020-12-31 0000818479 us-gaap:CustomerRelationshipsMember 2021-03-31 0000818479 us-gaap:CustomerRelationshipsMember 2020-12-31 0000818479 us-gaap:TrademarksAndTradeNamesMember 2021-03-31 0000818479 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0000818479 us-gaap:InProcessResearchAndDevelopmentMember 2021-03-31 0000818479 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0000818479 xray:TechnologiesAndEquipmentSegmentMember xray:EquipmentAndInstrumentsReportingUnitMember 2020-01-01 2020-03-31 0000818479 2018-01-11 2018-01-11 xray:reporting_unit 0000818479 2018-06-07 xray:distributor xray:stockholder 0000818479 2019-04-29 2019-04-29 0000818479 us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2012Member 2021-03-31 0000818479 us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2013Member 2021-03-31 0000818479 us-gaap:TaxYear2014Member us-gaap:InternalRevenueServiceIRSMember 2021-01-01 2021-03-31 0000818479 xray:SwedishTaxAgencyMember 2021-01-01 2021-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
Commission File Number 0-16211
DENTSPLY SIRONA Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 39-1434669
(State or other jurisdiction of |  | (I.R.S. Employer
incorporation or organization) |  | Identification No.)
13320 Ballantyne Corporate Place, Charlotte, North Carolina |  | 28277-3607
(Address of principal executive offices) |  | (Zip Code)

(844) 848-0137
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, par value $.01 per share | XRAY | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x | Accelerated filer ☐
Non-accelerated filer ☐ | Smaller reporting company ☐
| Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: At May 3, 2021, DENTSPLY SIRONA Inc. had 218,318,121 shares of common stock outstanding.

DENTSPLY SIRONA Inc.
TABLE OF CONTENTS

PART I | FINANCIAL INFORMATION | Page
Item 1 | Financial Statements (unaudited) | 3
| Consolidated Statements of Operations | 3
| Consolidated Statements of Comprehensive Income (Loss) | 4
| Consolidated Balance Sheets | 5
| Consolidated Statements of Changes in Equity | 6
| Consolidated Statements of Cash Flows | 7
| Notes to Unaudited Interim Consolidated Financial Statements | 8
Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 28
Item 3 | Quantitative and Qualitative Disclosures About Market Risk | 35
Item 4 | Controls and Procedures | 35
PART II | OTHER INFORMATION |
Item 1 | Legal Proceedings | 36
Item 1A | Risk Factors | 36
Item 2 | Unregistered Sales of Securities and Use of Proceeds | 36
Item 6 | Exhibits | 37
Signatures |  | 38

2

PART I – FINANCIAL INFORMATION
Item 1 – Financial Statements
DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
(unaudited)

|  |  | Three Months Ended March 31,
|  |  |  |  | 2021 |  | 2020
Net sales |  |  |  |  | $ | 1,027 |  |  | $ | 874 |
Cost of products sold |  |  |  |  | 448 |  |  | 406 |
Gross profit |  |  |  |  | 579 |  |  | 468 |
Selling, general, and administrative expenses |  |  |  |  | 385 |  |  | 359 |
Research and development expenses |  |  |  |  | 37 |  |  | 34 |
Goodwill impairment |  |  |  |  | — |  |  | 157 |
Restructuring and other costs |  |  |  |  | 3 |  |  | 43 |
Operating income (loss) |  |  |  |  | 154 |  |  | (125) |
Other income and expenses: |  |  |  |  |  |  |
Interest expense, net |  |  |  |  | 14 |  |  | 7 |
Other expense (income), net |  |  |  |  | (9) |  |  | (2) |
Income (loss) before income taxes |  |  |  |  | 149 |  |  | (130) |
Provision for income taxes |  |  |  |  | 32 |  |  | 10 |
Net income (loss) |  |  |  |  | 117 |  |  | (140) |
Less: Net income (loss) attributable to noncontrolling interest |  |  |  |  | — |  |  | — |
Net income (loss) attributable to Dentsply Sirona |  |  |  |  | $ | 117 |  |  | $ | (140) |
Net income (loss) per common share attributable to Dentsply Sirona: |  |  |  |  |  |
Basic |  |  |  |  | $ | 0.53 |  |  | $ | (0.63) |
Diluted |  |  |  |  | $ | 0.53 |  |  | $ | (0.63) |
Weighted average common shares outstanding: |  |  |  |  |  |  |
Basic |  |  |  |  | 218.8 |  |  | 220.9 |
Diluted |  |  |  |  | 219.9 |  |  | 220.9 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.
3

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in millions)
(unaudited)

|  |  | Three Months Ended March 31,
|  |  |  |  | 2021 |  | 2020
Net income (loss) |  |  |  |  | $ | 117 |  |  | $ | (140) |
Other comprehensive loss, net of tax: |  |  |  |  |  |  |
Foreign currency translation loss |  |  |  |  | (99) |  |  | (119) |
Net gain on derivative financial instruments |  |  |  |  | 5 |  |  | 5 |
Pension liability gain |  |  |  |  | 4 |  |  | 2 |
Total other comprehensive loss, net of tax |  |  |  |  | (90) |  |  | (112) |
Total comprehensive income (loss) |  |  |  |  | 27 |  |  | (252) |
Less: Comprehensive income (loss) attributable to noncontrolling interests |  |  |  |  | — |  |  | — |
Total comprehensive income (loss) attributable to Dentsply Sirona |  |  |  |  | $ | 27 |  |  | $ | (252) |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.
4

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except per share amounts)
(unaudited)

| March 31, 2021 |  | December 31, 2020
Assets |  |  |
Current Assets: |  |  |
Cash and cash equivalents | $ | 318 |  |  | $ | 438 |
Accounts and notes receivables-trade, net | 643 |  |  | 673 |
Inventories, net | 500 |  |  | 466 |
Prepaid expenses and other current assets | 235 |  |  | 214 |
Total Current Assets | 1,696 |  |  | 1,791 |
Property, plant, and equipment | 758 |  |  | 791 |
Operating lease right-of-use assets, net | 168 |  |  | 176 |
Identifiable intangible assets, net | 2,461 |  |  | 2,504 |
Goodwill | 3,952 |  |  | 3,986 |
Other noncurrent assets | 102 |  |  | 94 |
Total Assets | $ | 9,137 |  |  | $ | 9,342 |
Liabilities and Equity |  |  |
Current Liabilities: |  |  |
Accounts payable | $ | 283 |  |  | $ | 305 |
Accrued liabilities | 557 |  |  | 653 |
Income taxes payable | 44 |  |  | 60 |
Notes payable and current portion of long-term debt | 328 |  |  | 299 |
Total Current Liabilities | 1,212 |  |  | 1,317 |
Long-term debt | 1,923 |  |  | 1,978 |
Operating lease liabilities | 125 |  |  | 130 |
Deferred income taxes | 411 |  |  | 393 |
Other noncurrent liabilities | 536 |  |  | 554 |
Total Liabilities | 4,207 |  |  | 4,372 |
Equity: |  |  |
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued | — |  |  | — |
Common stock, $0.01 par value; | 3 |  |  | 3 |
400.0 million shares authorized, and 264.5 million shares issued at March 31, 2021 and December 31, 2020 |  |  |
218.2 million and 218.7 million shares outstanding at March 31, 2021 and December 31, 2020, respectively |  |  |
Capital in excess of par value | 6,618 |  |  | 6,604 |
Retained earnings | 1,328 |  |  | 1,233 |
Accumulated other comprehensive loss | (554) |  |  | (464) |
Treasury stock, at cost, 46.3 million and 45.8 million shares at March 31, 2021 and December 31, 2020, respectively | (2,468) |  |  | (2,409) |
Total Dentsply Sirona Equity | 4,927 |  |  | 4,967 |
Noncontrolling interests | 3 |  |  | 3 |
Total Equity | 4,930 |  |  | 4,970 |
Total Liabilities and Equity | $ | 9,137 |  |  | $ | 9,342 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.
5

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(in millions, except per share amounts)
(unaudited)

| Common Stock |  | Capital in Excess of Par Value |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Treasury Stock |  | Total Dentsply Sirona Equity |  | Noncontrolling Interests |  | Total Equity
Balance at December 31, 2020 | $ | 3 |  |  | $ | 6,604 |  |  | $ | 1,233 |  |  | $ | (464) |  |  | $ | (2,409) |  |  | $ | 4,967 |  |  | $ | 3 |  |  | $ | 4,970 |
Net income | — |  |  | — |  |  | 117 |  |  | — |  |  | — |  |  | 117 |  |  | — |  |  | 117 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | (90) |  |  | — |  |  | (90) |  |  | — |  |  | (90) |
Exercise of stock options | — |  |  | 11 |  |  | — |  |  | — |  |  | 22 |  |  | 33 |  |  | — |  |  | 33 |
Stock based compensation expense | — |  |  | 13 |  |  | — |  |  | — |  |  | — |  |  | 13 |  |  | — |  |  | 13 |
Funding of employee stock purchase plan | — |  |  | 1 |  |  | — |  |  | — |  |  | 2 |  |  | 3 |  |  | — |  |  | 3 |
Treasury shares purchased | — |  |  | — |  |  | — |  |  | — |  |  | (90) |  |  | (90) |  |  | — |  |  | (90) |
Restricted stock unit distributions | — |  |  | (11) |  |  | — |  |  | — |  |  | 7 |  |  | (4) |  |  | — |  |  | (4) |
Cash dividends ($0.1000 per share) | — |  |  | — |  |  | (22) |  |  | — |  |  | — |  |  | (22) |  |  | — |  |  | (22) |
Balance at March 31, 2021 | $ | 3 |  |  | $ | 6,618 |  |  | $ | 1,328 |  |  | $ | (554) |  |  | $ | (2,468) |  |  | $ | 4,927 |  |  | $ | 3 |  |  | $ | 4,930 |

| Common Stock |  | Capital in Excess of Par Value |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Treasury Stock |  | Total Dentsply Sirona Equity |  | Noncontrolling Interests |  | Total Equity
Balance at December 31, 2019 | $ | 3 |  |  | $ | 6,587 |  |  | $ | 1,404 |  |  | $ | (600) |  |  | $ | (2,301) |  |  | $ | 5,093 |  |  | $ | 2 |  |  | $ | 5,095 |
Net loss | — |  |  | — |  |  | (140) |  |  | — |  |  | — |  |  | (140) |  |  | — |  |  | (140) |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | (112) |  |  | — |  |  | (112) |  |  | — |  |  | (112) |
Exercise of stock options | — |  |  | — |  |  | — |  |  | — |  |  | 4 |  |  | 4 |  |  | — |  |  | 4 |
Stock based compensation expense | — |  |  | 9 |  |  | — |  |  | — |  |  | — |  |  | 9 |  |  | — |  |  | 9 |
Funding of employee stock purchase plan | — |  |  | 1 |  |  | — |  |  | — |  |  | 1 |  |  | 2 |  |  | — |  |  | 2 |
Treasury shares purchased | — |  |  | (28) |  |  | — |  |  | — |  |  | (112) |  |  | (140) |  |  | — |  |  | (140) |
Restricted stock unit distributions | — |  |  | (15) |  |  | — |  |  | — |  |  | 9 |  |  | (6) |  |  | — |  |  | (6) |
Cash dividends ($0.1000 per share) | — |  |  | — |  |  | (22) |  |  | — |  |  | — |  |  | (22) |  |  | — |  |  | (22) |
Balance at March 31, 2020 | $ | 3 |  |  | $ | 6,554 |  |  | $ | 1,242 |  |  | $ | (712) |  |  | $ | (2,399) |  |  | $ | 4,688 |  |  | $ | 2 |  |  | $ | 4,690 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.
6

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
(unaudited)

| Three Months Ended March 31,
| 2021 |  | 2020
Cash flows from operating activities: |  |  |
Net income (loss) | $ | 117 |  |  | $ | (140) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
Depreciation | 32 |  |  | 32 |
Amortization of intangible assets | 56 |  |  | 47 |
Amortization of deferred financing costs | 2 |  |  | 1 |
Goodwill impairment | — |  |  | 157 |
Indefinite-lived intangible asset impairment | — |  |  | 39 |
Deferred income taxes | (3) |  |  | (8) |
Stock based compensation expense | 13 |  |  | 10 |
Other non-cash expense | 17 |  |  | 10 |
Gain on sale of non-strategic businesses and product lines | (13) |  |  | — |
Changes in operating assets and liabilities, net of acquisitions: |  |  |
Accounts and notes receivable-trade, net | 11 |  |  | 53 |
Inventories, net | (50) |  |  | (57) |
Prepaid expenses and other current assets | (27) |  |  | (27) |
Other noncurrent assets | (13) |  |  | (7) |
Accounts payable | (17) |  |  | (29) |
Accrued liabilities | (81) |  |  | (95) |
Income taxes | (8) |  |  | 7 |
Other noncurrent liabilities | 13 |  |  | (3) |
Net cash provided by (used in) operating activities | 49 |  |  | (10) |
Cash flows from investing activities: |  |  |
Capital expenditures | (30) |  |  | (26) |
Cash paid for acquisitions of businesses and equity investments, net of cash acquired | (92) |  |  | — |
Cash received on sale of non-strategic businesses or product lines | 19 |  |  | — |
Cash received on derivative contracts | — |  |  | 9 |
Proceeds from sale of property, plant, and equipment | — |  |  | 1 |
Net cash used in investing activities | (103) |  |  | (16) |
Cash flows from financing activities: |  |  |
Proceeds on short-term borrowings | 30 |  |  | 31 |
Cash paid for treasury stock | (90) |  |  | (140) |
Cash dividends paid | (22) |  |  | (22) |
Proceeds from long-term borrowings, net of deferred financing costs | 4 |  |  | — |
Repayments on long-term borrowings, net | — |  |  | (1) |
Proceeds from exercised stock options | 33 |  |  | 4 |
Other financing activities, net | (8) |  |  | (2) |
Net cash used in financing activities | (53) |  |  | (130) |
Effect of exchange rate changes on cash and cash equivalents | (13) |  |  | (13) |
Net decrease in cash and cash equivalents | (120) |  |  | (169) |
Cash and cash equivalents at beginning of period | 438 |  |  | 405 |
Cash and cash equivalents at end of period | $ | 318 |  |  | $ | 236 |

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.
7

DENTSPLY SIRONA Inc. and Subsidiaries
NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2020.
The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein, are substantially the same as presented in the Company’s Form 10-K for the year ended December 31, 2020, except as may be indicated below.
Use of Estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ materially from those estimates.
Revenue Recognition
At March 31, 2021, the Company had $44 million of deferred revenue recorded predominantly in Accrued liabilities in the Consolidated Balance Sheets, with an immaterial portion recorded in Other noncurrent liabilities. The Company expects to recognize significantly all of this deferred revenue within the next 12 months.
Accounts and Notes Receivable
The Company records a provision for doubtful accounts, which is included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.
Accounts and notes receivables – trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $18 million at March 31, 2021 and $18 million at December 31, 2020.
Accounting Pronouncements Not Yet Adopted
In March 2020, the FASB issued ASU No. 2020-04 "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which was subsequently amended by ASU No. 2021-01 "Reference Rate Reform (Topic 848): Scope" in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate ("LIBOR") or another rate expected to be discontinued due to the reference rate reform. This standard is permitted to be adopted any time through December 31, 2022, and does not apply to contract modifications made or hedging relationships entered into or evaluated after December 31, 2022. The Company is currently assessing the impact that this standard will have on its financial position, results of operations, cash flows, and disclosures.
8

NOTE 2 – STOCK COMPENSATION
Total stock based compensation expense for non-qualified stock options, restricted stock units ("RSU"), and the tax related benefit for the three months ended March 31, 2021 and 2020 were as follows:

|  |  |  | Three Months Ended
(in millions) |  |  |  |  |  | 2021 |  | 2020
Stock option expense |  |  |  |  |  | $ | 2 |  |  | $ | 1 |
RSU expense |  |  |  |  |  | 11 |  |  | 8 |
Total stock based compensation expense |  |  |  |  |  | $ | 13 |  |  | $ | 9 |
Related deferred income tax benefit |  |  |  |  |  | $ | 2 |  |  | $ | 1 |

For the three months ended March 31, 2021 and 2020, stock compensation expense was $13 million and $9 million respectively, and was recorded in Selling, general, and administrative expense in the Consolidated Statements of Operations.
NOTE 3 – COMPREHENSIVE INCOME (LOSS)
Changes in Accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the three months ended March 31, 2021 and 2020 were as follows:

(in millions) |  | Foreign Currency Translation Gain (Loss) |  | Gain (Loss) on Cash Flow Hedges |  | Gain (Loss) on Net Investment Hedges |  |  |  | Pension Liability Gain (Loss) |  | Total
Balance, net of tax, at December 31, 2020 |  | $ | (187) |  |  | $ | (25) |  |  | $ | (119) |  |  |  |  | $ | (133) |  |  | $ | (464) |
Other comprehensive (loss) income before reclassifications and tax impact |  | (74) |  |  | (6) |  |  | 9 |  |  |  |  | 3 |  |  | (68) |
Tax (expense) benefit |  | (25) |  |  | 2 |  |  | (2) |  |  |  |  | (1) |  |  | (26) |
Other comprehensive (loss) income, net of tax, before reclassifications |  | (99) |  |  | (4) |  |  | 7 |  |  |  |  | 2 |  |  | (94) |
Amounts reclassified from accumulated other comprehensive income, net of tax |  | — |  |  | 2 |  |  | — |  |  |  |  | 2 |  |  | 4 |
Net (decrease) increase in other comprehensive loss |  | (99) |  |  | (2) |  |  | 7 |  |  |  |  | 4 |  |  | (90) |
Balance, net of tax, at March 31, 2021 |  | $ | (286) |  |  | $ | (27) |  |  | $ | (112) |  |  |  |  | $ | (129) |  |  | $ | (554) |

(in millions) |  | Foreign Currency Translation Gain (Loss) |  | Gain (Loss) on Cash Flow Hedges |  | Gain (Loss) on Net Investment Hedges |  |  |  |  |  | Pension Liability Gain (Loss) |  | Total
Balance, net of tax, at December 31, 2019 |  | $ | (368) |  |  | $ | (11) |  |  | $ | (101) |  |  |  |  |  |  | $ | (120) |  |  | $ | (600) |
Other comprehensive (loss) income before reclassifications and tax impact |  | (117) |  |  | (16) |  |  | 25 |  |  |  |  |  |  | — |  |  | (108) |
Tax (expense) benefit |  | (2) |  |  | 4 |  |  | (8) |  |  |  |  |  |  | — |  |  | (6) |
Other comprehensive (loss) income, net of tax, before reclassifications |  | (119) |  |  | (12) |  |  | 17 |  |  |  |  |  |  | — |  |  | (114) |
Amounts reclassified from accumulated other comprehensive income, net of tax |  | — |  |  | — |  |  | — |  |  |  |  |  |  | 2 |  |  | 2 |
Net (decrease) increase in other comprehensive loss |  | (119) |  |  | (12) |  |  | 17 |  |  |  |  |  |  | 2 |  |  | (112) |
Balance, net of tax, at March 31, 2020 |  | $ | (487) |  |  | $ | (23) |  |  | $ | (84) |  |  |  |  |  |  | $ | (118) |  |  | $ | (712) |

9

These amounts are recorded in AOCI, net of any related tax adjustments. At March 31, 2021 and December 31, 2020, the cumulative tax adjustments were $190 million and $216 million, respectively, primarily related to foreign currency translation gains and losses.
The cumulative foreign currency translation adjustments included translation losses of $159 million and $25 million at March 31, 2021 and December 31, 2020, respectively, and cumulative losses on loans designated as hedges of net investments of $127 million and $162 million, respectively. These foreign currency translation losses were partially offset by movements on derivative financial instruments.
Reclassifications out of AOCI to the Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020 were insignificant.
NOTE 4 – EARNINGS PER COMMON SHARE
The computation of basic and diluted earnings per common share for the three months ended March 31, 2021 and 2020 were as follows:

Basic Earnings (Loss) Per Common Share |  |  |  | Three Months Ended
(in millions, except per share amounts) |  |  |  |  |  | 2021 |  | 2020
Net income (loss) attributable to Dentsply Sirona |  |  |  |  |  | $ | 117 |  |  | $ | (140) |
Weighted average common shares outstanding |  |  |  |  |  | 218.8 |  |  | 220.9 |
Earnings (loss) per common share - basic |  |  |  |  |  | $ | 0.53 |  |  | $ | (0.63) |
Diluted Earnings (Loss) Per Common Share |  |  |  | Three Months Ended
(in millions, except per share amounts) |  |  |  |  |  | 2021 |  | 2020
Net income (loss) attributable to Dentsply Sirona |  |  |  |  |  | $ | 117 |  |  | $ | (140) |
Weighted average common shares outstanding |  |  |  |  |  | 218.8 |  |  | 220.9 |
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards |  |  |  |  |  | 1.1 |  |  | — |
Total weighted average diluted shares outstanding |  |  |  |  |  | 219.9 |  |  | 220.9 |
Earnings (loss) per common share - diluted |  |  |  |  |  | $ | 0.53 |  |  | $ | (0.63) |

The calculation of weighted average diluted common shares outstanding excluded 1.4 million of potentially diluted common shares because the Company reported a net loss for the three months ended March 31, 2020.
Stock options and RSUs of 0.8 million and 2.6 million equivalent shares of common stock outstanding during the three months ended March 31, 2021 and 2020, respectively were excluded from the computation of weighted average diluted shares outstanding because their effect would be antidilutive.
During the quarter ended March 31, 2021, the Company repurchased approximately 1.5 million shares pursuant to its open market shares repurchase plan for a net cost of $90 million at an average price of $60.62.
10

NOTE 5 – BUSINESS COMBINATIONS
Acquisitions
2021 Transactions
On January 21, 2021, the effective date of the transaction, the Company paid $94 million with the potential for additional earn-out provision payments of up to $10 million, to acquire 100% of the outstanding shares of Datum Dental, Ltd., a privately-owned producer and distributor of specialized regenerative dental material based in Israel. The fair value of the earn-out provision has been valued at $9 million as of the transaction date, resulting in a total purchase price of $103 million.
The preliminary fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows:

(in millions) |  |  |
Cash and cash equivalents |  | $ | 2 |  |
Other current assets |  | 2 |  |
Intangible assets |  | 81 |  |
Current liabilities |  | (2) |  |
Other long-term assets (liabilities), net |  | (13) |  |
Net assets acquired |  | 70 |  |
Goodwill |  | 33 |  |
Purchase consideration |  | $ | 103 |  |

The purchase price has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $33 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company. The goodwill is not expected to be deductible for tax purposes. Management is continuing to finalize its valuation of certain assets including other intangible assets and will conclude its valuation no later than one year from the acquisition date.
Identifiable intangible assets acquired were as follows:

|  |  |  | Weighted Average
|  |  |  | Useful Life
(in millions, except for useful life) |  | Amount |  | (in years)
Developed technology |  | $ | 70 |  |  | 15-20
In-process R&D |  | 11 |  |  | Indefinite
Total |  | $ | 81 |  |  |

2020 Transactions
On December 31, 2020, the effective date of the transaction, the Company acquired 100% of the outstanding interests of Straight Smile, LLC ("Byte"), a privately-held company, for approximately $1.0 billion using cash on hand. Byte is a doctor-directed, direct-to-consumer, clear aligner business. The acquisition is expected to enhance scale and accelerate the growth and profitability of the Company's combined clear aligners business.
The preliminary fair values of the assets acquired and liabilities assumed in connection with the Byte acquisition for the year ended December 31, 2020 were as follows:
11

(in millions) |  |  |
Cash and cash equivalents |  | $ | 13 |  |
Current assets |  | 17 |  |
Intangible assets |  | 416 |  |
Current liabilities |  | (30) |  |
Long-term assets (liabilities), net |  | 1 |  |
Net assets acquired |  | 417 |  |
Goodwill |  | 628 |  |
Purchase consideration |  | $ | 1,045 |  |

The purchase price has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, which resulted in the recording of $628 million in goodwill. The amount of goodwill is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company, including alignment with the Company’s existing clear aligner business, and is deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the first quarter of 2021 were immaterial to the financial statements, resulting in a reduction to goodwill of less than $3 million. Final determination of consideration as well as valuation of certain current assets are subject to a post-closing adjustment for the change in working capital to the date of closing, which is expected to be completed by the end of the second quarter of 2021.
Intangible assets acquired were as follows:

|  |  |  | Weighted Average
|  |  |  | Useful Life
(in millions, except for useful life) |  | Amount |  | (in years)
Non-compete agreements |  | $ | 16 |  |  | 5
Technology know-how |  | 210 |  |  | 10
Tradenames and trademarks |  | 190 |  |  | 20
Total |  | $ | 416 |  |  |

The results of operations for both the Byte and Datum businesses upon the effective date of each transaction have been included in the accompanying financial statements. These results, as well as the historical results for the above acquired businesses for the periods ended March 31, 2021 and 2020, are not material in relation to the Company’s net sales and earnings for those periods. The Company therefore does not believe these acquisitions represent material transactions either individually or in the aggregate requiring the supplemental pro-forma information prescribed by ASC 805 and accordingly, this information is not presented.
Divestitures
On February 1, 2021, the company disposed of an investment casting business previously included as part of the Consumables segment in exchange for a cash receipt of $19 million. The divestiture resulted in a gain of $13 million recorded in Other expense (income), net in the Consolidated Statements of Operations for the three months ended March 31, 2021.
NOTE 6 – SEGMENT INFORMATION
The Company’s two operating segments are organized primarily by product and generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating segments also comprise the Company’s reportable segments in accordance with how the Company’s chief operating decision-maker regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources.
12

The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, restructuring and other costs, interest expense, interest income, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions.
A description of the products and services provided within each of the Company’s two reportable segments is provided below.
Technologies & Equipment
This segment is responsible for the design, manufacture, and sales of the Company’s Dental Technology and Equipment Products and Healthcare Consumable Products. These products include dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as consumable medical device products.
Consumables
This segment is responsible for the design, manufacture, and sales of the Company’s Dental Consumable Products which include preventive, restorative, endodontic, and dental laboratory products.
The Company’s segment information for the three months ended March 31, 2021 and 2020 was as follows:
Net Sales

|  |  |  | Three Months Ended
(in millions) |  |  |  |  |  | 2021 |  | 2020
Technologies & Equipment |  |  |  |  |  | $ | 597 |  |  | $ | 520 |
Consumables |  |  |  |  |  | 430 |  |  | 354 |
Total net sales |  |  |  |  |  | $ | 1,027 |  |  | $ | 874 |

Segment Adjusted Operating Income

|  |  |  | Three Months Ended
(in millions) |  |  |  |  |  | 2021 |  | 2020
Technologies & Equipment |  |  |  |  |  | $ | 126 |  |  | $ | 111 |
Consumables |  |  |  |  |  | 150 |  |  | 62 |
Segment adjusted operating income |  |  |  |  |  | 276 |  |  | 173 |
Reconciling items expense (income): |  |  |  |  |  |  |  |
All other (a) |  |  |  |  |  | 62 |  |  | 49 |
Goodwill impairment |  |  |  |  |  | — |  |  | 157 |
Restructuring and other costs |  |  |  |  |  | 3 |  |  | 43 |
Interest expense |  |  |  |  |  | 14 |  |  | 7 |
Other expense (income), net |  |  |  |  |  | (9) |  |  | (2) |
Amortization of intangible assets |  |  |  |  |  | 55 |  |  | 47 |
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations |  |  |  |  |  | 2 |  |  | 2 |
Income (loss) before income taxes |  |  |  |  |  | $ | 149 |  |  | $ | (130) |

(a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.
13

NOTE 7 – INVENTORIES
Inventories are stated at the lower of cost and net realizable value. All of the Company's inventories were determined by the first-in, first-out (“FIFO”) or average cost methods, with the exception of immaterial amounts determined using the last-in, first-out ("LIFO") method totaling $1 million and $3 million at March 31, 2021 and December 31, 2020, respectively.
Inventories, net were as follows:

(in millions) |  | March 31, 2021 |  | December 31, 2020
Finished goods |  | $ | 303 |  |  | $ | 264 |
Work-in-process |  | 75 |  |  | 68 |
Raw materials and supplies |  | 122 |  |  | 134 |
Inventories, net |  | $ | 500 |  |  | $ | 466 |

The Company's inventory reserve was $95 million and $117 million at March 31, 2021 and December 31, 2020, respectively.
NOTE 8 – RESTRUCTURING AND OTHER COSTS
During the three months ended March 31, 2021, the Company recorded net restructuring and other costs of $1 million which consists of $3 million in severance and other restructuring related costs offset by $2 million in adjustments to inventory reserves.
During the three months ended March 31, 2020, the Company recorded restructuring and other costs of $42 million which consists of asset impairments of $39 million and severance costs of $3 million.
The details of total restructuring and other costs for the three months ended March 31 were as follows:

Affected Line Item in the Consolidated Statements of Operations |  |  |  | Three Months Ended |
(in millions) |  |  |  |  |  | 2021 |  | 2020 |
Cost of products sold |  |  |  |  |  | $ | (2) |  |  | $ | — |  |
Selling, general, and administrative expenses |  |  |  |  |  | — |  |  | (1) |  |
Restructuring and other costs |  |  |  |  |  | 3 |  |  | 43 |  |
Total restructuring and other costs |  |  |  |  |  | $ | 1 |  |  | $ | 42 |  |

The Company announced on August 6, 2020 that it will exit its traditional orthodontics business as well as both exit and restructure certain portions of its laboratory business. The traditional orthodontics business is part of the Technologies & Equipment segment and the laboratory business is part of the Consumables segment. The Company is exiting several of its facilities and reducing its workforce by approximately 4% to 5%. The Company expects to record restructuring charges in a range of $60 million to $70 million for inventory write-downs, severance costs, fixed asset write-offs, and other facility closure costs. The Company recorded total expenses of approximately $57 million related to these actions which consists primarily of inventory write-downs of approximately $29 million, accelerated depreciation of approximately $14 million, and severance costs of approximately $9 million. For the three months ended March 31, 2021, the Company made a $2 million adjustment related to inventory reserves. The Company expects most of the remaining restructuring charges will be recorded during the second quarter of 2021.
14

The Company’s restructuring accruals at March 31, 2021 were as follows:

|  | Severance
(in millions) |  | 2019 and Prior Plans |  | 2020 Plans |  | 2021 Plans |  | Total
Balance at December 31, 2020 |  | $ | 12 |  |  | $ | 17 |  |  | $ | — |  |  | $ | 29 |
Provisions |  | 1 |  |  | — |  |  | 2 |  |  | 3 |
Amounts applied |  | (7) |  |  | (7) |  |  | — |  |  | (14) |
Change in estimates |  | — |  |  | (1) |  |  | — |  |  | (1) |
Balance at March 31, 2021 |  | $ | 6 |  |  | $ | 9 |  |  | $ | 2 |  |  | $ | 17 |

|  | Other Restructuring Costs
(in millions) |  | 2019 and Prior Plans |  | 2020 Plans |  | 2021 Plans |  | Total
Balance at December 31, 2020 |  | $ | 3 |  |  | $ | 2 |  |  | $ | — |  |  | $ | 5 |
Provisions |  | 1 |  |  | — |  |  | — |  |  | 1 |
Amounts applied |  | (1) |  |  | (1) |  |  | — |  |  | (2) |
Balance at March 31, 2021 |  | $ | 3 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 4 |

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:

(in millions) |  | December 31, 2020 |  | Provisions |  | Amounts Applied |  | Change in Estimates |  | March 31, 2021
Technologies & Equipment |  | $ | 16 |  |  | $ | — |  |  | $ | (8) |  |  | $ | (1) |  |  | $ | 7 |
Consumables |  | 17 |  |  | 3 |  |  | (7) |  |  |  |  | 13 |
All Other |  | 1 |  |  | 1 |  |  | (1) |  |  | — |  |  | 1 |
Total |  | $ | 34 |  |  | $ | 4 |  |  | $ | (16) |  |  | $ | (1) |  |  | $ | 21 |

The associated restructuring liabilities are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets.
NOTE 9 – FINANCIAL INSTRUMENTS AND DERIVATIVES
Derivative Instruments and Hedging Activities
The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and equity. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company has utilized interest rate swaps to convert variable rate debt to fixed rate debt. The Company does not hold derivative instruments for trading or speculative purposes.
Derivative Instruments
The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at March 31, 2021 and the notional amounts expected to mature during the next 12 months.
15

(in millions) |  | Aggregate Notional Amount |  | Aggregate Notional Amount Maturing within 12 Months
Cash Flow Hedges |  |  |  |
Foreign exchange forward contracts |  | $ | 230 |  |  | $ | 169 |
Total derivative instruments designated as cash flow hedges |  | $ | 230 |  |  | $ | 169 |
Hedges of Net Investments |  |  |  |
Cross currency basis swaps |  | $ | 309 |  |  | 309 |
Total derivative instruments designated as hedges of net investments |  | $ | 309 |  |  | $ | 309 |
Fair Value Hedges |  |  |  |
Foreign exchange forward contracts |  | $ | 240 |  |  | 104 |
Total derivative instruments designated as fair value hedges |  | $ | 240 |  |  | $ | 104 |
Derivative Instruments not Designated as Hedges |  |  |  |
Foreign exchange forward contracts |  | $ | 218 |  |  | 218 |
Total derivative instruments not designated as hedges |  | $ | 218 |  |  | $ | 218 |

Cash Flow Hedges
Foreign Exchange Risk Management
The Company uses a program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company accounts for the designated foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions.
Interest Rate Risk Management
The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
AOCI Release
Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At March 31, 2021, the Company expects to reclassify $7 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 3, Comprehensive (Loss) Income.
16

Hedges of Net Investments in Foreign Operations
The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in derivative and non-derivative financial instruments; which are designated as hedges of net investments and are included in AOCI. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign exchange forward contracts and cross currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross currency swap basis rates, and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.
Fair Value Hedges
Foreign Exchange Risk Management
The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.
On January 6, 2021 the Company entered into foreign exchange forward contracts with a notional value of SEK 1.3 billion as a result of an increase in intercompany loans denominated in Swedish kronor. The foreign exchange forwards are designated as fair value hedges.
Derivative Instruments Not Designated as Hedges
The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in cash from operating activities in the Consolidated Statements of Cash Flows.
Gains and (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three months ended March 31, 2021 and 2020 were insignificant.
Derivative Instrument Activity
The amount of gains and losses recorded in AOCI in the Consolidated Balance Sheets, Costs of products sold, Interest expense, and Other expense (income), net in the Company's Consolidated Statement of Operations related to all derivative instruments were as follows:
17

|  | March 31, 2021
(in millions) |  | Gain (Loss) in AOCI |  | Consolidated Statements of Operations Location |  | Effective Portion Reclassified from AOCI into Income (Expense) |  |  |  | Recognized in Income (Expense)
Cash Flow Hedges |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | (6) |  |  | Cost of products sold |  | $ | (1) |  |  |  |  | $ | — |
Interest rate swaps |  | (29) |  |  | Interest expense |  | (1) |  |  |  |  | — |
Total for cash flow hedging |  | $ | (35) |  |  |  |  | $ | (2) |  |  |  |  | $ | — |
Hedges of Net Investments |  |
Cross currency basis swaps |  | $ | 9 |  |  | Interest expense |  | $ | — |  |  |  |  | $ | 2 |
Total for net investment hedging |  | $ | 9 |  |  |  |  | $ | — |  |  |  |  | $ | 2 |
Fair Value Hedges |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | — |  |  | Other (expense) income, net |  | $ | — |  |  |  |  | $ | 16 |
Total for fair value hedging |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | 16 |

|  | March 31, 2020
(in millions) |  | Gain (Loss) in AOCI |  | Consolidated Statements of Operations Location |  | Effective Portion Reclassified from AOCI into Income (Expense) |  | Recognized in Income (Expense)
Cash Flow Hedges |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 2 |  |  | Cost of products sold |  | $ | 1 |  |  | $ | 1 |
Interest rate swaps |  | (18) |  |  | Interest expense |  | (1) |  |  | — |
Total for cash flow hedging |  | $ | (16) |  |  |  |  | $ | — |  |  | $ | 1 |
Hedges of Net Investments |  |
Cross currency basis swaps |  | $ | 9 |  |  | Interest expense |  | $ | — |  |  | $ | 2 |
Foreign exchange forward contracts |  | 16 |  |  | Other expense (income), net |  | — |  |  | 6 |
Total for net investment hedging |  | $ | 25 |  |  |  |  | $ | — |  |  | $ | 8 |

For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 3, Comprehensive Income (Loss).
18

Consolidated Balance Sheets Location of Derivative Fair Values
The fair value and the location of the Company's derivatives in the Consolidated Balance Sheets were as follows:

|  | March 31, 2021
(in millions) |  | Prepaid Expenses and Other Current Assets |  | Other Noncurrent Assets |  | Accrued Liabilities |  | Other Noncurrent Liabilities
Designated as Hedges: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 6 |  |  | $ | 9 |  |  | $ | 6 |  |  | $ | 1 |
Cross currency basis swaps |  | — |  |  | — |  |  | 10 |  |  | — |
Total |  | $ | 6 |  |  | $ | 9 |  |  | $ | 16 |  |  | $ | 1 |
Not Designated as Hedges: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 1 |  |  | $ | — |  |  | $ | 3 |  |  | $ | — |
Total |  | $ | 1 |  |  | $ | — |  |  | $ | 3 |  |  | $ | — |
|  | December 31, 2020
(in millions) |  | Prepaid Expenses and Other Current Assets |  | Other Noncurrent Assets |  | Accrued Liabilities |  | Other Noncurrent Liabilities
Designated as Hedges: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 5 |  |  | $ | 2 |  |  | $ | 10 |  |  | $ | 3 |
Cross currency basis swaps |  | — |  |  | — |  |  | 20 |  |  | — |
Total |  | $ | 5 |  |  | $ | 2 |  |  | $ | 30 |  |  | $ | 3 |
Not Designated as Hedges: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 3 |  |  | $ | — |  |  | $ | 2 |  |  | $ | — |
Total |  | $ | 3 |  |  | $ | — |  |  | $ | 2 |  |  | $ | — |

Balance Sheet Offsetting
Substantially all of the Company’s derivative contracts are subject to netting arrangements; whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.
19

Offsetting of financial assets and liabilities under netting arrangements at March 31, 2021 were as follows:

|  |  |  |  |  |  |  | Gross Amounts Not Offset in the Consolidated Balance Sheets |  |
(in millions) |  | Gross Amounts Recognized |  | Gross Amount Offset in the Consolidated Balance Sheets |  | Net Amounts Presented in the Consolidated Balance Sheets |  | Financial Instruments |  | Cash Collateral Received/Pledged |  | Net Amount
Assets |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |  |  | $ | (10) |  |  | $ | — |  |  | $ | 6 |
Total assets |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |  |  | $ | (10) |  |  | $ | — |  |  | $ | 6 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 10 |  |  | $ | — |  |  | $ | 10 |  |  | $ | (6) |  |  | $ | — |  |  | $ | 4 |
Cross currency basis swaps |  | 10 |  |  | — |  |  | 10 |  |  | (4) |  |  | — |  |  | 6 |
Total liabilities |  | $ | 20 |  |  | $ | — |  |  | $ | 20 |  |  | $ | (10) |  |  | $ | — |  |  | $ | 10 |

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2020 were as follows:

|  |  |  |  |  |  |  | Gross Amounts Not Offset in the Consolidated Balance Sheets |  |
(in millions) |  | Gross Amounts Recognized |  | Gross Amount Offset in the Consolidated Balance Sheets |  | Net Amounts Presented in the Consolidated Balance Sheets |  | Financial Instruments |  | Cash Collateral Received/Pledged |  | Net Amount
Assets |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 9 |  |  | $ | — |  |  | $ | 9 |  |  | $ | (9) |  |  | $ | — |  |  | $ | — |
Total assets |  | $ | 9 |  |  | $ | — |  |  | $ | 9 |  |  | $ | (9) |  |  | $ | — |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 15 |  |  | $ | — |  |  | $ | 15 |  |  | $ | — |  |  | $ | — |  |  | $ | 15 |
Interest rate swaps |  | 20 |  |  | — |  |  | 20 |  |  | (7) |  |  | — |  |  | 13 |
Total liabilities |  | $ | 35 |  |  | $ | — |  |  | $ | 35 |  |  | $ | (7) |  |  | $ | — |  |  | $ | 28 |

NOTE 10 – FAIR VALUE MEASUREMENT
Assets and liabilities measured at fair value on a recurring basis
The Company estimated the fair value and carrying value of its total long term debt, including current portion was $2,382 million and $2,251 million, respectively, at March 31, 2021. At December 31, 2020, the Company estimated the fair value and carrying value of this debt were $2,509 million and $2,281 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company’s public debt or is determined by discounting future cash flows using interest rates available at March 31, 2021 and December 31, 2020 to companies with similar credit ratings for issues with similar terms and maturities. It is considered a Level 2 fair value measurement.
20

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:

|  | March 31, 2021
(in millions) |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |  |  | $ | — |
Total assets |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |
Cross currency basis swaps |  | $ | 10 |  |  | $ | — |  |  | $ | 10 |  |  | $ | — |
Foreign exchange forward contracts |  | 10 |  |  | — |  |  | 10 |  |  | — |
Contingent considerations on acquisitions |  | 13 |  |  | — |  |  | — |  |  | 13 |
Total liabilities |  | $ | 33 |  |  | $ | — |  |  | $ | 20 |  |  | $ | 13 |

|  | December 31, 2020
(in millions) |  | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | $ | 10 |  |  | $ | — |  |  | $ | 10 |  |  | $ | — |
Total assets |  | $ | 10 |  |  | $ | — |  |  | $ | 10 |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |
Cross currency basis swaps |  | $ | 20 |  |  | $ | — |  |  | $ | 20 |  |  | $ | — |
Foreign exchange forward contracts |  | 15 |  |  | — |  |  | 15 |  |  | — |
Contingent considerations on acquisitions |  | 5 |  |  | — |  |  | — |  |  | 5 |
Total liabilities |  | $ | 40 |  |  | $ | — |  |  | $ | 35 |  |  | $ | 5 |

There have been no transfers between levels during the three months ended March 31, 2021.
NOTE 11 – INCOME TAXES
Uncertainties in Income Taxes
The Company recognizes the impact of a tax position in the interim consolidated financial statements if that position is more likely than not of being sustained on audit based on the technical merits of the position.
It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date of the Company’s quarterly consolidated financial statements. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next 12 months are not expected to be significant.
Other Tax Matters
During the three months ended March 31, 2021, the Company recorded $1 million of tax benefit for other discrete tax matters. The Company also recorded a $4 million tax expense as a discrete item related to business divestitures.
During the three months ended March 31, 2020, the Company recorded $6 million of tax expense for discrete tax matters. The Company also recorded a $11 million tax benefit as a discrete item related to the indefinite-lived intangible asset impairment charge.
21

NOTE 12 – FINANCING ARRANGEMENTS
At March 31, 2021, the Company had $1,139 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit facility.
The Company has a $500 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-stop credit facility for the Company's commercial paper program. At March 31, 2021 and December 31, 2020, there were no outstanding borrowings under the multi-currency revolving credit facility. The company borrowed and had $27 million outstanding under the commercial paper facility at March 31, 2021 and no outstanding borrowings under the commercial paper facility at December 31, 2020.
Additionally, at both March 31, 2021 and December 31, 2020, the Company had multiple short-term facilities available as a result of the following actions taken in 2020 to strengthen its liquidity and flexibility in response to the COVID-19 pandemic:
•On April 9, 2020, the Company entered into a $310 million 364-day revolving credit facility which matured on April 8, 2021. As of March 31, 2021 there were no outstanding borrowings under this facility.
•On April 17, 2020, the Company provided a notice to the administrative agent to draw down the full available amount under the 2018 Credit Facility, which is equal to $700 million. The Company had previously not drawn down any sums under this facility. The borrowings incurred interest at the rate of adjusted LIBOR plus 1.25%. The Company subsequently repaid the $700 million revolver borrowing on May 26, 2020.
•On May 26, 2020, the Company issued $750 million of senior unsecured notes with a final maturity date of June 1, 2030 at a semi-annual coupon rate of 3.25%. The net proceeds were $748 million, net of discount of $2 million. Issuance fees totaled $6 million. The Company paid $31 million to settle the $150 million notional Treasury Rate Lock ("T-Lock") contract which partially hedged the interest rate risk of the note issuance. This cost will be amortized over the ten-year life of the notes. The proceeds were used to repay the $700 million borrowed against the 2018 Credit Facility and the remaining proceeds will be used for working capital and other general corporate purposes.
•During the second quarter of 2020 the company entered into various other credit facilities including a 40 million euro 364-day revolving credit facility which matured on April 30, 2021, a 30 million euro 364-day revolving credit facility with a maturity date of May 6, 2021, and a 3.3 billion Japanese yen 364-day revolving credit facility with a maturity date of June 11, 2021. As of March 31, 2021 there were no outstanding borrowings under these facilities.
The Company’s revolving credit facilities and senior unsecured notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. At March 31, 2021, the Company was in compliance with all affirmative and negative debt covenants.
NOTE 13 – GOODWILL AND INTANGIBLE ASSETS
The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually during the second quarter, or from time to time when warranted by facts and circumstances. In conjunction with the most recent annual test of goodwill at April 30, 2020, the Company applied a hypothetical sensitivity analysis to its reporting units. If the discount rate of these reporting units had been hypothetically increased by 100 basis points, or, in a separate test, each reporting unit were subject to a 10% hypothetical reduction in fair value, it is noted that the Implants reporting unit would have had a fair value approximating book value. For the Equipment & Instruments reporting unit which recorded an impairment during the first quarter of 2020, the implied fair value was found to approximate net book value at April 30, 2020, and therefore this reporting unit is noted to be sensitive to any unfavorable change in assumptions. Goodwill associated with the Implants and Equipment & Instruments reporting units was $1,222 million and $292 million respectively as of March 31, 2021.
22

The Company also previously applied a hypothetical sensitivity analysis as part of the April 30, 2020 annual impairment test of indefinite-lived intangibles. It was noted that if the fair value of each of these indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 100 basis points at April 30, 2020, the fair value of these assets would still exceed their book value, with the exception of certain assets including tradenames and trademarks related to the Equipment & Instruments reporting unit for which an impairment was previously recorded in March 2020. For these assets, the implied fair values continued to approximate net book values at April 30, 2020 and are therefore noted to be sensitive to any unfavorable changes in assumptions. At March 31, 2021, the remaining indefinite-lived tradenames and trademarks related to the Equipment & Instruments reporting unit was $79 million.
During the time subsequent to the annual evaluation, and at March 31, 2021, the Company considered whether any events or changes in circumstances had resulted in the likelihood that the goodwill or indefinite-lived intangible assets may have been impaired. It is management's assessment that no such events have occurred. A change in any of the estimates and assumptions used in the annual test, a decline in the overall markets or in the use of intangible assets among other factors, could have a negative material impact to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings.
A reconciliation of changes in the Company’s goodwill by reportable segment were as follows:

(in millions) |  | Technologies & Equipment |  | Consumables |  | Total
Balance at December 31, 2020 |  | $ | 3,092 |  |  | $ | 894 |  |  | $ | 3,986 |
Acquisition related additions |  | 33 |  |  | — |  |  | 33 |
Divestiture of a business |  | — |  |  | (3) |  |  | (3) |
Measurement period adjustments on prior acquisitions |  | (3) |  |  | — |  |  | (3) |
Effects of exchange rate changes |  | (47) |  |  | (14) |  |  | (61) |
Balance at March 31, 2021 |  | $ | 3,075 |  |  | $ | 877 |  |  | $ | 3,952 |

The gross carrying amount of goodwill and the cumulative goodwill impairment were as follows:

|  | March 31, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Cumulative Impairment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Cumulative Impairment |  | Net Carrying Amount
Technologies & Equipment |  | $ | 5,968 |  |  | $ | (2,893) |  |  | $ | 3,075 |  |  | $ | 5,985 |  |  | $ | (2,893) |  |  | $ | 3,092 |
Consumables |  | 877 |  |  | — |  |  | 877 |  |  | 894 |  |  | — |  |  | 894 |
Total effect of cumulative impairment |  | $ | 6,845 |  |  | $ | (2,893) |  |  | $ | 3,952 |  |  | $ | 6,879 |  |  | $ | (2,893) |  |  | $ | 3,986 |

23

Identifiable definite-lived and indefinite-lived intangible assets were as follows:

|  | March 31, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Developed technology and patents |  | $ | 1,702 |  |  | $ | (685) |  |  | $ | 1,017 |  |  | $ | 1,681 |  |  | $ | (677) |  |  | $ | 1,004 |
Tradenames and trademarks |  | 269 |  |  | (70) |  |  | 199 |  |  | 273 |  |  | (70) |  |  | 203 |
Licensing agreements |  | 36 |  |  | (30) |  |  | 6 |  |  | 37 |  |  | (30) |  |  | 7 |
Customer relationships |  | 1,112 |  |  | (500) |  |  | 612 |  |  | 1,142 |  |  | (494) |  |  | 648 |
Total definite-lived |  | $ | 3,119 |  |  | $ | (1,285) |  |  | $ | 1,834 |  |  | $ | 3,133 |  |  | $ | (1,271) |  |  | $ | 1,862 |
Indefinite-lived tradenames and trademarks |  | $ | 616 |  |  | $ | — |  |  | $ | 616 |  |  | $ | 642 |  |  | $ | — |  |  | $ | 642 |
In-process R&D (a) |  | 11 |  |  | — |  |  | 11 |  |  | — |  |  | — |  |  | — |
Total indefinite-lived |  | $ | 627 |  |  | $ | — |  |  | $ | 627 |  |  | $ | 642 |  |  | $ | — |  |  | $ | 642 |
Total identifiable intangible assets |  | $ | 3,746 |  |  | $ | (1,285) |  |  | $ | 2,461 |  |  | $ | 3,775 |  |  | $ | (1,271) |  |  | $ | 2,504 |

(a) Intangible assets acquired in a business combination that are in-process and used in research and development ("R&D") activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed.
During the three months ended March 31, 2020, as a result of updating the estimates and assumptions pertaining to the impact of the ongoing COVID-19 pandemic the Company determined that the goodwill associated with the Equipment & Instruments reporting unit within the Technologies & Equipment segment was impaired. As a result, the Company recorded a goodwill impairment charge of $157 million. During the same period, the Company also recorded impairment charges of $39 million related to indefinite-lived intangible assets within the Technologies & Equipment segment driven by a decline in forecasted sales as a result of the COVID-19 pandemic as well as an unfavorable change in the discount rate.
NOTE 14 – COMMITMENTS AND CONTINGENCIES
Litigation
On January 11, 2018, Tom Redlich, a former employee, filed a lawsuit against the Company, demanding supplemental compensation pursuant to an agreement allegedly entered into with Sirona Dental GmbH which was intended to entice Mr. Redlich to continue to work for the company for no less than eight years following the date of this agreement. The Company filed its response on April 4, 2018, denying the authenticity and enforceability of, and all liability under, the alleged agreement. Mr. Jost Fischer, upon invitation of the Company, joined the litigation against Mr. Redlich as a third party. In his submission to the Court, Mr. Fischer disputed the central allegations raised by Mr. Redlich in his lawsuit. The Court held several hearings in the matter, and then closed the hearings in June 2019 pending the Court’s decision on the capacity of Mr. Fischer to enter into a binding agreement of the type alleged by Mr. Redlich in the manner alleged. On November 5, 2019, the Company received the Court’s judgment rejecting Mr. Redlich’s lawsuit and dismissing his claims. Mr. Redlich appealed in December 2019 and the Company filed its response in January 2020 seeking to uphold the Court’s ruling. On February 27, 2020, the Company received the Appellate Court’s decision rejecting Mr. Redlich’s appeal and upholding the decision of the lower court dismissing his claims. The Court of Appeals has denied Mr. Redlich the right to file a further appeal in this matter, however, on March 23, 2020, Mr. Redlich filed an extraordinary appeal with the Austrian Supreme Court. On March 30, 2021, the Austrian Supreme Court rejected Mr. Redlich's appeal, leaving Mr. Redlich with no further possibility or right of appeal in this case.
24

On January 25, 2018, Futuredontics, Inc., a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Calethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato), the parties to each action are in the process of finalizing the settlement terms, and the parties will then seek court approval of the settlements. The expected settlement amount, which is immaterial to the financial statements, has been recorded as an accrued liability within the Company's consolidated balance sheet as of March 31, 2021.
On June 7, 2018, and August 9, 2018, two putative class action suits were filed, and later consolidated, in the Supreme Court of the State of New York, County of New York claiming that the Company and certain individual defendants, violated U.S. securities laws (the "State Court Action") by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the Merger. The amended complaint alleges that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company's products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company's stock in the Merger. On September 26, 2019, the Court granted the Company's motion to dismiss all claims and a judgment dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs' post-judgment motion to vacate or modify the judgment and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the post-judgment motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court's decision dismissing the action. The plaintiffs' appeals and the Company's cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision.
On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants (the "Federal Class Action"). The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company's stock during the period February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. On January 8, 2021, the parties filed a stipulation, which is subject to the Court's approval, (1) withdrawing the Company's motion to dismiss without prejudice, (2) allowing plaintiff to file a second amended complaint by January 22, 2021, and (3) providing for a briefing schedule on a motion to dismiss that will be completed by May 13, 2021. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021.
25

On April 29, 2019, two purported stockholders of the Company filed a derivative action on behalf of the Company in the U.S. District Court for the District of Delaware against the Company's directors (the "Stockholder's Derivative Action"). Based on allegations similar to those asserted in the class actions described above, the plaintiffs allege that the directors caused the Company to misrepresent its business prospects and thereby subjected the Company to multiple securities class actions and other litigation. On September 20, 2019, the plaintiffs in the Stockholder's Derivative Action filed an amended derivative complaint on behalf of the Company in the U.S. District Court for the District of Delaware against the Company's directors. The plaintiffs assert claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and violations of the U.S. securities laws. The plaintiffs seek relief that includes, among other things, monetary damages and various corporate governance reforms. The Company filed a motion to dismiss, and on July 31, 2020 the Magistrate Judge issued a report and recommendation to the District Court Judge recommending dismissal of the case with prejudice. On September 25, 2020, the District Court Judge issued an order adopting the Magistrate Judge’s report dismissing the case, but without prejudice, and provided the plaintiffs with three weeks to file a motion to amend their complaint. On October 16, 2020, the plaintiffs filed a notice advising the Court that they would not be amending their complaint. On October 23, 2020, the Court issued an order dismissing the case with prejudice as to the plaintiffs. The same day, the plaintiffs submitted a letter to the Board of Directors demanding that the Board investigate and commence legal proceedings against the same current and former directors and officers of the Company previously named as defendants in the Stockholder's Derivative Action on the basis of the same claims alleged in the Stockholder's Derivative Action. On November 6, 2020, the Company sent a letter to counsel for the plaintiffs stating that the Board would consider the litigation demand and respond with its decision. On March 25, 2021, the Company sent a letter to counsel for the plaintiffs relaying that the Board considered the litigation demand, and determined that it was not in the best interests of the Company to pursue the actions identified in the litigation demand. On April 8, 2021, the plaintiffs submitted a letter in response, requesting certain documents from the Company related to the Board’s decision to refuse the litigation demand. On April 19, 2021, counsel for the Company responded to plaintiffs' April 8, 2021 letter, explaining the reasons why plaintiffs are not entitled to the requested documents.
The Company intends to defend itself vigorously in these actions.
As a result of an audit by the IRS for fiscal years 2012 through 2013, on February 11, 2019, the IRS issued to the Company a “30-day letter” and a Revenue Agent’s Report (“RAR”), relating to the Company’s worthless stock deduction in 2013 in the amount of $546 million. The RAR disallows the deduction and, after adjusting the Company’s net operating loss carryforward, asserts that the Company is entitled to a refund of $5 million for 2012, has no tax liability for 2013, and owes a deficiency of $17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company’s 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Appeals Office Team on October 28, 2020 and, on November 13, 2020, submitted a supplemental response to questions raised by the Appeals Team. The Company’s position continues to be reviewed by the IRS Appeals Office team. The Company believes the IRS' position is without merit and believes that it is more likely-than-not the Company’s position will be sustained in 2021 upon further review by the IRS Appeals Office Team. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those inherent in the valuation of various assets at the time of the worthless stock deduction, and those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute would result in a current period charge to earnings and could have a material adverse effect in the consolidated results of operations, financial position, and liquidity of the Company.
The Swedish Tax Agency has disallowed certain of the Company’s interest expense deductions for the tax years from 2013 to 2018. If such interest expense deductions were disallowed, the Company would be subject to an additional $57 million in tax expense. The Company has appealed the disallowance to the Swedish Administrative Court. With respect to such deductions taken in the tax years from 2013 to 2014, the Court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish Administrative Court. On November 5, 2018, the Company delivered its final argument to the Administrative Court of Appeals at a hearing. The European Union Commission has taken the view that Sweden’s interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. This view has now been confirmed by the European Union Court of Justice in a preliminary ruling requested by the Swedish Supreme Administrative Court in a pending case. The Company intends to vigorously defend its position and pursue related appeals.
26

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity.
While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.
Commitments
From time to time, the Company enters into long-term inventory purchase commitments with minimum purchase requirements for raw materials and finished goods to ensure the availability of products for production and distribution. Future minimum annual payments for inventory purchase commitments were immaterial as of March 31, 2021.
27

DENTSPLY SIRONA Inc. and Subsidiaries
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations
Information included in or incorporated by reference in this Form 10-Q, and other filings with the U.S. Securities and Exchange Commission (the “SEC”) and the Company’s press releases or other public statements, contains or may contain forward-looking statements. Please refer to a discussion of the Company’s forward-looking statements and associated risks in Part I, “Forward-Looking Statements,” Part I, Item 1, “Business” and Part I, Item 1A, "Risk Factors" of the Company's Form 10-K for the year ended December 31, 2020. See updated risk factors in Part II, Item 1A, "Risk Factors" of this Form 10-Q.
Company Profile
DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company"), is the world’s largest manufacturer of professional dental products and technologies, with a 134-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental equipment and dental consumable products under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality, and effective solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona’s worldwide headquarters is located in Charlotte, North Carolina. The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY.
BUSINESS
The Company operates in two operating segments, Technologies & Equipment and Consumables.
The Technologies & Equipment segment is responsible for the design, manufacture, sales and distribution of the Company’s Dental Technology and Equipment Products and Healthcare Consumable Products. These products include dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as consumable medical device products.
The Consumables segment is responsible for the design, manufacture, sales and distribution of the Company’s Dental Consumable Products which include preventive, restorative, endodontic, and dental laboratory products.
The impact of COVID-19 and the Company’s response
Information pertaining to the impact of the COVID-19 pandemic on the Company's operations and financial results during the course of 2020 as well as the Company's overall response can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. Updates to that summary of impact for the three months ended March 31, 2021 are as follows:
•Continuing the trend from the second half of 2020, the Company has continued to see demand improve and dental patient traffic normalize in most markets. While government authorities have lifted many of their restrictions, the end dates for all restrictions being lifted are still unknown. It is also uncertain when customer demand will fully return to pre-COVID-19 levels upon lifting these restrictions.
•The Company's COVID-19 infection crisis management process implemented in 2020 remains in effect, and there have been no significant disruptions to operations as a result of infections. During the course of the pandemic, the Company has utilized this process to manage several incidents of exposure at facilities. All potential and actual cases have been reviewed to ensure that the Company managed exposed employees appropriately, consistently and safely. None of these incidents have resulted in a material loss of production or financial impact to the results for the three months ended March 31, 2021.
•The Company previously undertook various initiatives during the second quarter of 2020, to ensure its ongoing liquidity which included, among other actions, entering into a $310 million revolving credit facility on April 9, 2020, a 40 million euro revolving credit on May 5, 2020, a 30 million euro revolving credit facility on May 12, 2020 and 3.3 billion Japanese yen revolving credit facility on June 11, 2020. These additional short-term facilities were entered into in an abundance of caution and are all set to expire during the second quarter. At March 31, 2021, there were no outstanding borrowings under these facilities.
28

•During the first quarter the Company has continued to prioritize employee safety and preventing the possible spread of COVID-19 by encouraging ongoing work-from-home where possible and maintaining travel restrictions.
Up through the date of the filing of this Form 10-Q, the Company’s principal manufacturing facilities and other operations have remained operational at a more normalized level than during the preceding year. The Company continues to monitor the COVID-19 pandemic. As governmental authorities adjust restrictions globally, the Company plans to appropriately staff sales, manufacturing, and other functions to meet customer demand and deliver on continuing critical projects while also complying with all government requirements.
Restructuring Announcement
In November 2018, the Board of Directors of the Company approved a plan to restructure and simplify the Company’s business. The goal of the restructuring is to drive annualized net sales growth of 3% to 4% and adjusted operating income margins of 22% by the end of 2022 as well as achieve net annual cost savings of $200 million to $225 million by 2021. In July 2020, the Board of Directors of the Company approved an expansion of this plan that is intended to further optimize the Company’s product portfolio and reduces operating expenses. The product portfolio optimization has resulted in the divestiture or closure of certain underperforming businesses. The operating expense reductions will come as a result of additional leverage from continued integration and simplification of the business. The Company had initially anticipated one-time expenditures and charges of approximately $275 million yielding annual cost savings of $200 million to $225 million by 2021. The program expansion is expected to result in total charges of approximately $375 million and annual cost savings of approximately $250 million. The Company expects that these expanded actions will result in incremental global headcount reductions of 6% to 7% in addition to the original projections of 6% to 8%. Since November 2018, the Company has incurred expenditures of approximately $314 million under this program, of which, approximately $122 million were non-cash charges. These amounts include the charges for the portfolio shaping initiatives announced on August 6, 2020 which are further discussed below.
As part of this expanded plan, the Company announced on August 6, 2020 that it will exit its traditional orthodontics business as well as both exit and restructure certain portions of its laboratory business. The traditional orthodontics business is part of the Technologies & Equipment segment and the laboratory business is part of the Consumables segment. The Company is exiting several of its facilities and reducing its workforce by approximately 4% to 5%. The Company expects to record restructuring charges in a range of $60 million to $70 million for inventory write-downs, severance costs, fixed asset write-offs, and other facility closure costs. The Company estimates that $45 million to $55 million of the restructuring charges will be non-cash charges related to inventory write-downs and fixed asset write-offs. The Company has recorded expenses of approximately $57 million related to these actions, of which approximately $46 million were non-cash charges. For the three months ended March 31, 2021, the Company made a $2 million adjustment related to inventory reserves. The Company expects most of the remaining restructuring charges will be recorded during the second quarter of 2021.
RESULTS OF OPERATIONS, THREE MONTHS ENDED MARCH 31, 2021 COMPARED TO THREE MONTHS ENDED MARCH 31, 2020
Net Sales
The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also compares net sales on an organic sales basis, which is a Non-GAAP measure.
The Company defines "organic sales" as the increase or decrease in net sales excluding: (1) net sales from acquired and divested businesses recorded prior to the first anniversary of the acquisition or divestiture, (2) net sales attributable to discontinued product lines in both the current and prior year periods, and (3) the impact of foreign currency translation, which is calculated by comparing current-period sales to prior-period sales, with both periods converted to the U.S. dollar rate at local currency foreign exchange rates for each month of the prior period.
The "organic sales" measure is not calculated in accordance with US GAAP; therefore, this item represents a Non-GAAP measure. This Non-GAAP measure may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Organic sales is an important internal measure for the Company. The Company's senior management receives a monthly analysis of operating results that includes organic sales. The performance of the Company is measured on this metric along with other performance metrics.
29

The Company discloses organic sales to allow investors to evaluate the performance of the Company’s operations exclusive of certain items that impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this information is helpful in understanding underlying net sales trends.

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
Net sales |  | $ | 1,027 |  |  | $ | 874 |  |  | $ | 153 |  |  | 17.5 | %

Net sales for the three months ended March 31, 2021 were $1,027 million, an increase of $153 million or 17.5% from the three months ended March 31, 2020. The increase in net sales was attributable to both the Technologies & Equipment and Consumables segments which were impacted by overall higher volumes during the first quarter partly due to a recovery in demand from the impact of the COVID-19 pandemic. During the three months ended March 31, 2020, the Company saw normal sales levels for the months of January and February and started to experience a decline in sales volume during March due to the onset of the pandemic. As a result, organic sales increased 12.1% in the first three months of 2021 relative to the comparative quarter.
Net sales were also positively impacted by approximately 5.3% due to the weakening of the U.S. dollar as compared to the same prior year period as well as a benefit of 5.1% from acquisitions offset by a reduction of 5.0% due to divestitures of non-strategic businesses and discontinued products.
Net Sales by Region
Net sales by geographic region were as follows:

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
United States |  | $ | 347 |  |  | $ | 300 |  |  | $ | 47 |  |  | 15.7 | %
Europe |  | 418 |  |  | 373 |  |  | 45 |  |  | 12.1 | %
Rest of World |  | 262 |  |  | 201 |  |  | 61 |  |  | 30.3 | %

United States
The increase in net sales was attributable to both the Technologies & Equipment and the Consumables segments and was primarily due to overall higher volumes during the quarter following periods of lower demand resulting from the COVID-19 pandemic. As a result, organic sales increased by 4.8% as compared to the same prior year period. The increase in net sales also included a benefit of 14.8% from acquisitions offset by a reduction of 5.3% due to divestitures of non-strategic businesses and discontinued products.
Europe
The increase in net sales was attributable to both the Consumables and the Technologies & Equipment segments and was primarily due to overall higher volumes during the quarter following periods of lower demand resulting from the COVID-19 pandemic. As a result, organic sales increased by 8.1% as compared to the same prior year period. Net sales for the quarter ended March 31, 2021 was also positively impacted by 8.6% due to the weakening of the U.S. dollar as compared to the same prior year period, offset by a reduction of 4.6% due to divestitures of non-strategic businesses and discontinued products.
30

Rest of World
The increase in net sales was attributable to both the Consumables and the Technologies & Equipment segments and was primarily due to the negative impact in the comparative quarter of 2020 from the COVID-19 pandemic. During the three months ended March 31, 2020, the Company started to experience a decline in sales volume during March due to the COVID-19 pandemic, particularly in China and other Asian markets. As a result, organic sales increased by 30.8% as compared to the same prior year period. Net sales for the quarter ended March 31, 2021 was also positively impacted by 5.0% due to the weakening of the U.S. dollar as compared to the same prior year period, as well as a benefit of 0.1% from acquisitions offset by a reduction of 5.6% due to divestitures of non-strategic businesses and discontinued products.
Gross Profit

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
Gross profit |  | $ | 579 |  |  | $ | 468 |  |  | $ | 111 |  |  | 23.7 | %
Gross profit as a percentage of net sales |  | 56.4 | % |  | 53.5 | % |  |  |  |

Gross profit as a percentage of net sales increased by 290 basis points for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020, primarily driven by favorable mix and the increase in net sales for higher margin products.
Operating Expenses

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
Selling, general and administrative expenses ("SG&A") |  | $ | 385 |  |  | $ | 359 |  |  | $ | 26 |  |  | 7.2 | %
Research and development expenses ("R&D") |  | 37 |  |  | 34 |  |  | 3 |  |  | 8.8 | %
Goodwill impairment |  | — |  |  | 157 |  |  | (157) |  |  | NM
Restructuring and other costs |  | 3 |  |  | 43 |  |  | (40) |  |  | NM
SG&A as a percentage of net sales |  | 37.5 | % |  | 41.1 | % |  |  |  |

NM - Not meaningful
SG&A Expenses
SG&A expenses as a percentage of net sales decreased 360 basis points for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020, primarily driven by greater absorption of expenses due to higher sales as well as continued expense discipline.
R&D Expenses
The increase in R&D expenses from the comparable quarter of prior year was primarily due to an increase in spending on product development initiatives particularly in our Technology & Equipment businesses and in research investments specific to our recent acquisitions of Byte and Datum Dental.
Goodwill Impairment
There were no impairments recorded in the three months ended March 31, 2021. During the three months ended March 31, 2020, as a result of updating the estimates and assumptions pertaining to the impact of the ongoing COVID-19 pandemic the Company determined that the goodwill associated with the Equipment & Instruments reporting unit within the Technologies & Equipment segment was impaired. As a result, the Company recorded a goodwill impairment charge of $157 million.
Restructuring and Other Cost
In connection with the various restructuring initiatives, as described earlier, the Company recorded restructuring costs of $3 million for the three months ended March 31, 2021.
31

During the three months ended March 31, 2020, the Company recorded $2 million of restructuring costs and $41 million of other costs, which consisted primarily of impairment charges of $39 million related to indefinite-lived intangible assets within the Technologies & Equipment segment driven by a decline in forecasted sales as a result of the COVID-19 pandemic as well as an unfavorable change in the discount rate.
Other Income and Expense

|  | Three Months Ended March 31,
(in millions) |  | 2021 |  | 2020 |  | Change
Net interest expense |  | $ | 14 |  |  | $ | 7 |  |  | $ | 7 |
Other expense (income), net |  | (9) |  |  | (2) |  |  | (7) |
Net interest and other expense |  | $ | 5 |  |  | $ | 5 |  |  | $ | — |

The increase in net interest expense was due to higher average debt levels during the three months ended March 31, 2021 compared to the prior year period.
The increase in other expense (income), net for the three months ended March 31, 2021 was primarily due to a $13 million gain on a sale of a business during the three months ended March 31, 2021.
Income Taxes and Net Income (Loss)

|  | Three Months Ended March 31,
(in millions, except per share data and percentages) |  | 2021 |  | 2020 |  | $ Change
Provision for income taxes |  | $ | 32 |  |  | $ | 10 |  |  | $ | 22 |
Effective income tax rate |  | 21.5 | % |  | (7.7) | % |  |
Net income (loss) attributable to Dentsply Sirona |  | $ | 117 |  |  | $ | (140) |  |  | $ | 257 |

Provision for income taxes
For the three months ended March 31, 2021, the provision for income taxes was $32 million as compared to a provision of $10 million during the three months ended March 31, 2020.
During the three months ended March 31, 2021, the Company recorded $1 million of tax benefit for other discrete tax matters. The Company also recorded a $4 million tax expense as a discrete item related to business divestitures.
During the three months ended March 31, 2020, the Company recorded $6 million tax expense for other discrete matters. The Company also recorded a $11 million tax benefit as a discrete item related to the indefinite-lived intangible asset impairment charge.
The Company continues to reassess the realizability of its deferred tax assets and, after weighing all positive and negative evidence, continues to maintain a valuation allowance on certain deferred tax assets.
32

Segment Results
Net Sales

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
Technologies & Equipment |  | $ | 597 |  |  | $ | 520 |  |  | $ | 77 |  |  | 14.8% |
Consumables |  | 430 |  |  | 354 |  |  | 76 |  |  | 21.5% |

Segment Adjusted Operating Income

|  | Three Months Ended March 31,
(in millions, except percentages) |  | 2021 |  | 2020 |  | $ Change |  | % Change
Technologies & Equipment |  | $ | 126 |  |  | $ | 111 |  |  | $ | 15 |  |  | 13.5% |
Consumables |  | 150 |  |  | 62 |  |  | 88 |  |  | 141.9% |

Technologies & Equipment
The increase in net sales occurred across all dental businesses and was the result of overall higher volumes during the first quarter partly due to demand recovery from the impact of the COVID-19 pandemic, partially offset by decreased sales in the Healthcare business. As a result, organic sales increased 5.8% as compared to the same prior year period, driven primarily by the Equipment & Instruments and Implants businesses. Net sales were also positively impacted by approximately 5.7% due to the weakening of the U.S. dollar over the prior year period, as well as a benefit of 8.6% from acquisitions offset by a reduction of 5.3% due to divestitures of non-strategic businesses and discontinued products.
The adjusted operating income increase was primarily driven by the increase in net sales as well as continued expense discipline.
Consumables
The increase in net sales occurred across all regions and was primarily due to overall higher volumes during the first quarter partly due to demand recovery from the impact in 2020 from the COVID-19 pandemic. As a result, organic sales increased 21.2% as compared to the same prior year period, primarily driven by the Endodontic, Restorative, and Preventive businesses. Net sales were also positively impacted by approximately 4.6% due to the weakening of the U.S. dollar as compared to the same prior year period, offset by a reduction of 4.3% due to divestitures of non-strategic businesses and discontinued products.
The adjusted operating income increase was primarily driven by favorable mix including increased volumes for higher margin products, and continued expense discipline.
CRITICAL ACCOUNTING POLICIES
There have been no significant changes to the critical accounting policies as disclosed in the Company’s Form 10-K for the year ended December 31, 2020.
LIQUIDITY AND CAPITAL RESOURCES
Cash provided by operating activities during the three months ended March 31, 2021 was $49 million, an increase of $59 million as compared to a use of $10 million during the three months ended March 31, 2020. This increase was driven primarily by the higher cash flow impact of net income in the current period. Additionally, cash collections during the comparative three-month period of 2020 were adversely impacted by the onset of the COVID-19 pandemic late in the quarter.
33

For the three months ended March 31, 2021, on a constant currency basis, the number of days of sales outstanding in accounts receivable increased by 2 day to 56 days as compared to 54 days at December 31, 2020. On a constant currency basis, the number of days of sales in inventory increased by 11 days to 113 days at March 31, 2021 as compared to 102 days at December 31, 2020. The Company calculates “constant currency basis” by removing the impact of foreign currency translation, which is calculated by comparing current-period sales, accounts receivables, and inventory to prior-period sales, accounts receivable, and inventory, with both periods converted to the U.S. dollar rate at local currency foreign exchange rates for each month of the prior period.
Cash used in investing activities during the first three months of 2021 included net cash paid for acquisitions of $92 million and capital expenditures of $30 million, offset by the receipt of $19 million in net cash from the sale of a non-core business. The Company expects critical capital expenditures to be in the range of approximately $150 million to $170 million for the full year 2021.
Cash used in financing activities for the three months ended March 31, 2021 was primarily related to net share repurchases of $90 million and dividend payments of $22 million. Financing inflows consisted of proceeds from the exercise of stock options of $33 million and additional short-term borrowings of $30 million, primarily through the Company's commercial paper program.
The Company’s overall cash and cash equivalents decreased by $120 million to $318 million during the three months ended March 31, 2021.
During the three months ended March 31, 2021, the Company repurchased approximately 1.5 million shares under its open market share repurchase plan for a cost of $90 million at a weighted average price of $60.62. Including prior year repurchases, the total amount repurchased under this authorization is $740 million leaving $260 million available to be repurchased. Additional share repurchases, if any, will be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors.
The Company's total borrowings decreased by a net $26 million during the three months ended March 31, 2021, driven by $60 million due to exchange rate fluctuations on debt denominated in foreign currencies. At March 31, 2021 and December 31, 2020, the Company's ratio of total net debt to total capitalization was 28.2% and 27.0%, respectively. The Company defines net debt as total debt, including current and long-term portions, less cash and cash equivalents, and total capitalization as the sum of net debt plus equity.
In response to the COVID-19 pandemic, the Company previously took actions during the course of 2020 to strengthen its liquidity and financial flexibility. See the Company's most recently filed Form 10-K for more information.
At March 31, 2021, the Company had a borrowing capacity of $1,139 million available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. Through the date of the filing of this Form 10-Q, the Company has no outstanding borrowings under any of its credit facilities.
These agreements are unsecured and contain certain affirmative and negative covenants relating to the operations and financial condition of the Company. The most restrictive of these covenants pertain to asset dispositions and prescribed ratios of indebtedness to total capital and operating income, plus depreciation and amortization to interest expense. At March 31, 2021, the Company was in compliance with these covenants and expects to remain in compliance with all covenants over the next twelve months.
At March 31, 2021, the Company held $54 million of precious metals on consignment from several financial institutions. The consignment agreements allow the Company to acquire the precious metals at market rates at a point in time which is approximately the same time and for the same price as alloys are sold to the Company's customers. In the event that the financial institutions would discontinue offering these consignment arrangements, and if the Company could not obtain other comparable arrangements, the Company may be required to obtain third party financing to fund an ownership position in the required precious metal inventory levels.
34

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operating activities and future foreign investments. The Company has the ability to repatriate additional funds to the U.S., which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At March 31, 2021, management believed that sufficient liquidity was available in the United States and expects this to remain for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations, however, these particular repatriation activities have not and are not expected to result in a significant incremental tax liability to the Company.
Except as stated above, there have been no material changes to the Company's scheduled contractual cash obligations disclosed in its Form 10-K for the year ended December 31, 2020.
The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near-term as interest rates remain at historically low levels. The Company believes there is sufficient liquidity available for the next twelve months.
NEW ACCOUNTING PRONOUNCEMENTS
Refer to Part 1, Item 1, Note 1, Significant Accounting Policies, to the Unaudited Interim Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.
Item 3 – Quantitative and Qualitative Disclosures about Market Risk
There have been no significant material changes to the market risks as disclosed in the Company’s Form 10-K for the year ended December 31, 2020.
Item 4 – Controls and Procedures
Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There have been no changes in the Company’s internal control over financial reporting that occurred during the three months ended March 31, 2021, that have materially affected, or are likely to materially affect, its internal control over financial reporting.
35

PART II – OTHER INFORMATION
Item 1 – Legal Proceedings
Reference to Part I, Item 1, Note 14 Commitments and Contingencies, in the Notes to Unaudited Interim Consolidated Financial Statements of this Form 10-Q.
Item 1A – Risk Factors
There have been no significant material changes to the risk factors as disclosed in Part 1A, “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2020.
Item 2 – Unregistered Sales of Securities and Use of Proceeds
At March 31, 2021, the Company had $260 million available under the stock repurchase program. During the three months ended March 31, 2021, the Company had the following activity with respect to this repurchase program:

(in millions, except per share amounts) |  | Total Number of Shares Purchased |  | Average Price Paid Per Share |  | Total Cost of Shares Purchased |  | Dollar Value of Shares that May be Purchased Under the Stock Repurchase Program
Period |  |  |  |
January 1, 2021 to January 31, 2021 |  | — |  |  | $ | — |  |  | $ | — |  |  | $ | 350 |
February 1, 2021 to February 28, 2021 |  | — |  |  | — |  |  | — |  |  | 350 |
March 1, 2021 to March 31, 2021 |  | 1.5 |  |  | 60.62 |  |  | 90 |  |  | 260 |
|  | 1.5 |  |  | $ | — |  |  | $ | 90 |  |  |

36

Item 6 – Exhibits

Exhibit Number |  | Description
31.1 |  | Section 302 Certification Statement Chief Executive Officer
31.2 |  | Section 302 Certification Statement Chief Financial Officer
32 |  | Section 906 Certification Statements
101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH |  | XBRL Taxonomy Extension Schema Document
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | XBRL Extension Labels Linkbase Document
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

37

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DENTSPLY SIRONA Inc.

/s/ | Donald M. Casey, Jr. |  | May 6, 2021
| Donald M. Casey, Jr. |  | Date
| Chief Executive Officer |  |

/s/ | Jorge M. Gomez |  | May 6, 2021
| Jorge M. Gomez |  | Date
| Executive Vice President and |  |
| Chief Financial Officer |  |

38